Overview

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Status:
RECRUITING

Trial end date:
2033-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).

Phase:

PHASE1

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators:

Dracen Pharmaceuticals, Inc.
Fibrolamellar Cancer Foundation

Treatments:

durvalumab